SECTION D / READERS WRITE
Tirzepatide, frequently asked.
Twelve answers based on the published evidence and the FDA label. Not medical advice; for your specific situation, talk to a clinician.
What is tirzepatide and how does it work?
Tirzepatide is a 39-amino-acid peptide medicine that activates two gut-hormone receptors at the same time: the receptor for GIP (glucose-dependent insulinotropic polypeptide) and the receptor for GLP-1 (glucagon-like peptide-1). Both are incretin hormones released after meals; together they tell the pancreas to release insulin when blood glucose rises, slow gastric emptying, suppress glucagon, and reduce appetite. By engaging both receptors with a single molecule — and by binding GIP with native-like potency while biasing GLP-1 signaling toward sustained cyclic-AMP generation — tirzepatide produces larger blood-sugar and body-weight reductions than selective GLP-1 agonists in head-to-head trials [1][2][6].
How is tirzepatide different from semaglutide?
Semaglutide is a selective GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 agonist. That single difference cascades into measurable clinical separation. In SURPASS-2 (head-to-head, type 2 diabetes), tirzepatide 15 mg reduced HbA1c by 2.30% versus 1.86% with semaglutide 1 mg, and produced roughly double the weight loss (12.4 kg vs 6.2 kg) over 40 weeks [2]. In SURMOUNT-5 (head-to-head, obesity), tirzepatide produced 20.2% mean weight loss versus 13.7% with semaglutide over 72 weeks [6]. The safety profiles overlap heavily; the most notable difference is slightly higher discontinuation due to gastrointestinal events with tirzepatide at the highest dose.
What conditions is tirzepatide FDA-approved to treat?
Three. (1) Type 2 diabetes in adults, as an adjunct to diet and exercise — approved May 2022. (2) Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related condition — approved November 2023. (3) Moderate-to-severe obstructive sleep apnea in adults with obesity — approved December 2024 [3]. The drug is not FDA-approved for type 1 diabetes, for use in pediatric populations, for pregnancy, or for any cardiovascular, hepatic, or heart-failure indication — though the SUMMIT and SYNERGY-NASH trials suggest those indications may be on the horizon [7][8].
How much weight do people typically lose on tirzepatide?
It depends on the dose, the indication, and how long the person stays on therapy. In SURMOUNT-1 (adults with obesity, no diabetes), mean weight reductions over 72 weeks were 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg [5]. In SURMOUNT-2 (obesity + type 2 diabetes), reductions were smaller — 13.4% at 10 mg, 15.7% at 15 mg [15]. In SURMOUNT-3 (after a structured lifestyle lead-in), total mean reduction was 26.6%. The drug is not a step-change for everyone — approximately 9 in 10 SURMOUNT-1 participants lost weight, but individual responses vary widely, and the highest doses produce the largest losses only in patients who can tolerate them [5].
What are the most common side effects?
Gastrointestinal events dominate the safety profile: nausea, diarrhea, constipation, vomiting, decreased appetite, abdominal pain. They are most common during titration and tend to diminish at maintenance doses [20]. Less common but more serious: acute pancreatitis (~0.2% in trials, similar to placebo), gallbladder events, acute kidney injury secondary to volume depletion, hypersensitivity reactions, and hypoglycemia (especially when combined with insulin or sulfonylureas). The FDA label carries a boxed warning for thyroid C-cell tumors based on rat carcinogenicity data; the drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome [12].
How is tirzepatide dosed?
Subcutaneous injection, once weekly, with a six-step titration. The schedule is 2.5 mg for four weeks, then 5 mg, then 7.5 mg, then 10 mg, then 12.5 mg, then 15 mg — each step at least four weeks long. Maintenance doses are 5, 10, or 15 mg depending on indication, tolerance, and treatment goal. The 2.5 mg starting dose is purely for tolerance; clinical efficacy begins at 5 mg [3][12]. See the dosage page for the full schedule and the pharmacokinetic rationale.
What is the half-life of tirzepatide?
Approximately 5 days — roughly 116-120 hours in humans. Peak plasma concentration occurs 24 to 72 hours after injection, and steady state is reached after about four weeks of weekly dosing [11]. The long half-life is achieved by attaching a C20 fatty diacid tail to the peptide, which binds to serum albumin and shields the drug from renal filtration and proteolytic degradation [10].
Does tirzepatide help with heart failure or sleep apnea?
Both have positive Phase 3 trial data. SURMOUNT-OSA (NEJM, 2024) tested tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity. Over 52 weeks, the apnea-hypopnea index dropped by roughly 25 events per hour and body weight by roughly 20%. The FDA approved the OSA indication in December 2024 [18]. SUMMIT (NEJM, 2025) tested tirzepatide in HFpEF (heart failure with preserved ejection fraction) and obesity, and reduced the composite of cardiovascular death or worsening heart failure by 38% over a median 104 weeks. Heart failure is not yet an FDA-approved indication [7].
What happens when you stop taking tirzepatide?
SURMOUNT-4 (JAMA, 2024) was designed to answer this exact question. After a 36-week open-label tirzepatide lead-in (during which participants lost a mean of 20.9% of body weight), participants were randomized to continue tirzepatide or switch to placebo. Over the following 52 weeks, the placebo group regained 14% of body weight; the continued-tirzepatide group lost an additional 6.7%. The between-group difference was 20.4 percentage points [17]. This pattern — substantial regain after discontinuation — supports a chronic-disease pharmacotherapy model and is consistent with the broader incretin-agonist class.
Is tirzepatide safe long-term?
The longest controlled human exposure to date is roughly 4 years (median follow-up in SURPASS-CVOT, the cardiovascular outcomes trial in 13,165 patients with type 2 diabetes) [9]. Across that exposure, the safety profile remained consistent with shorter trials — gastrointestinal events the most common reason for discontinuation, pancreatitis rare, no new unexpected signals. Beyond 4 years, data are limited. Open questions include effects on bone density, muscle mass beyond trial windows, and outcomes after long-term discontinuation. The boxed warning about thyroid C-cell tumors remains based on rodent data, not human findings [12].
How does tirzepatide affect the liver?
Favorably, in the patient population that has been studied. SYNERGY-NASH (NEJM, 2024) randomized 190 adults with biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis) and stage 2 or 3 fibrosis to tirzepatide or placebo for 52 weeks. Resolution of MASH without worsening of fibrosis occurred in 51-62% of tirzepatide-treated participants versus 10% on placebo. Fibrosis improvement (a secondary endpoint) was also observed [8]. Tirzepatide is not yet FDA-approved for MASH; SYNERGY-NASH was a Phase 2 study and confirmatory Phase 3 trials are ongoing.
What is SURPASS-CVOT and what did it show?
SURPASS-CVOT is the cardiovascular outcomes trial — the trial regulators require to confirm that a new diabetes drug does not increase cardiovascular risk. It enrolled 13,165 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, randomized 1:1 to tirzepatide or to dulaglutide (an active comparator, already known to reduce cardiovascular events). Published in NEJM in late 2025, the trial met its non-inferiority endpoint for three-point MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), with an 8% relative reduction in MACE and a 16% reduction in all-cause mortality favoring tirzepatide. Discontinuation for adverse events was modestly higher with tirzepatide (13.3% vs 10.2%) [9].